Nomura Holdings Inc. Purchases Shares of 4,841 ResMed Inc. (NYSE:RMD)

Nomura Holdings Inc. bought a new position in shares of ResMed Inc. (NYSE:RMD - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,841 shares of the medical equipment provider's stock, valued at approximately $1,107,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Colonial Trust Co SC grew its position in shares of ResMed by 6,250.0% during the 4th quarter. Colonial Trust Co SC now owns 127 shares of the medical equipment provider's stock valued at $29,000 after buying an additional 125 shares during the last quarter. Optiver Holding B.V. acquired a new position in ResMed in the fourth quarter valued at approximately $33,000. Itau Unibanco Holding S.A. grew its holdings in shares of ResMed by 1,000.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 165 shares of the medical equipment provider's stock valued at $38,000 after purchasing an additional 150 shares during the last quarter. OFI Invest Asset Management bought a new position in shares of ResMed during the fourth quarter valued at approximately $39,000. Finally, Coppell Advisory Solutions LLC raised its position in shares of ResMed by 1,750.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 185 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 175 shares during the period. 54.98% of the stock is owned by institutional investors and hedge funds.

ResMed Price Performance

Shares of RMD stock traded down $0.29 during midday trading on Thursday, reaching $245.49. 644,419 shares of the company were exchanged, compared to its average volume of 1,021,607. The company's 50 day moving average price is $227.00 and its two-hundred day moving average price is $234.34. The company has a market cap of $36.00 billion, a P/E ratio of 28.98, a PEG ratio of 1.53 and a beta of 0.78. ResMed Inc. has a 12 month low of $179.42 and a 12 month high of $263.05. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 EPS for the quarter, beating analysts' consensus estimates of $2.36 by $0.01. ResMed had a net margin of 25.34% and a return on equity of 26.17%. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same quarter last year, the business earned $2.13 earnings per share. The business's revenue for the quarter was up 7.9% on a year-over-year basis. On average, sell-side analysts expect that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Thursday, May 8th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Thursday, May 8th. ResMed's dividend payout ratio (DPR) is presently 23.79%.

Insider Transactions at ResMed

In related news, insider Kaushik Ghoshal sold 9,745 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $239.31, for a total transaction of $2,332,075.95. Following the completion of the transaction, the insider now owns 9,725 shares of the company's stock, valued at $2,327,289.75. This trade represents a 50.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Witte Jan De sold 2,000 shares of the business's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $243.47, for a total transaction of $486,940.00. Following the completion of the sale, the director now owns 5,806 shares in the company, valued at approximately $1,413,586.82. This trade represents a 25.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,949 shares of company stock valued at $11,822,260. Corporate insiders own 0.71% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on RMD. Mizuho set a $265.00 price objective on ResMed in a research report on Wednesday, April 16th. Royal Bank of Canada raised their target price on ResMed from $247.00 to $255.00 and gave the company a "sector perform" rating in a research note on Thursday, April 24th. KeyCorp set a $274.00 price target on shares of ResMed in a report on Thursday, April 24th. Needham & Company LLC reaffirmed a "hold" rating on shares of ResMed in a report on Friday, January 31st. Finally, Wall Street Zen upgraded shares of ResMed from a "hold" rating to a "buy" rating in a research report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $258.83.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.